ALNYLAM PHARMACEUTICALS, INC.: revenue
| Value | {"amount": 219750000, "concept": "us-gaap:Revenues", "currency": "USD"} |
|---|---|
| Period | 2019-01-01 – 2019-12-31 |
| Status | current |
| Entity | ALNYLAM PHARMACEUTICALS, INC. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T11:51:53.022865+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/b4ac35b5-b4d3-4f6c-b6ec-f3e0f106b78d
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001178670-22-000013Retrieved: 2026-08-19T11:51:53.022865+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001178670/revenue/2019-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/b4ac35b5-b4d3-4f6c-b6ec-f3e0f106b78d
History
- supersedes {"amount": 219750000, "concept": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "currency": "USD"} (evidence 0001178670-20-000004)